Dissemin is shutting down on January 1st, 2025

Published in

Nature Research, Nature, 7437(494), p. 390-390, 2013

DOI: 10.1038/nature11864

Nature Research, Nature, 7402(486), p. 266-270, 2012

DOI: 10.1038/nature11114

Elsevier, European Journal of Cancer, (48), p. S26-S27

DOI: 10.1016/s0959-8049(12)70812-2

Links

Tools

Export citation

Search in Google Scholar

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma

Journal article published in 2012 by Louise van der Weyden, Jelle J. ten Hoeve, Jeroen de Ridder, Pedro A. Pérez-Mancera, L. Van Der Weyden, Alistair G. Rust, Pérez Mancera Pa, Glen Kristiansen, Louise van der Weyden, Pedro A. Perez-Mancera, S. Knight, Allen Li, Aaron L. Sarver, Kevin A. T. Silverstein, Petra Rummele and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Pancreatic ductal adenocarcinoma (PDA) remains a lethal malignancy despite much progress concerning its molecular characterization. PDA tumours harbour four signature somatic mutations(1-4) in addition to numerous lower frequency genetic events of uncertain significance(5). Here we use Sleeping Beauty (SB) transposon-mediated insertional mutagenesis(6,7) in a mouse model of pancreatic ductal preneoplasia(8) to identify genes that cooperate with oncogenic Kras(G12D) to accelerate tumorigenesis and promote progression. Our screen revealed new candidate genes for PDA and confirmed the importance of many genes and pathways previously implicated in human PDA. The most commonly mutated gene was the X-linked deubiquitinase Usp9x, which was inactivated in over 50% of the tumours. Although previous work had attributed a pro-survival role to USP9X in human neoplasia(9), we found instead that loss of Usp9x enhances transformation and protects pancreatic cancer cells from anoikis. Clinically, low USP9X protein and messenger RNA expression in PDA correlates with poor survival after surgery, and USP9X levels are inversely associated with metastatic burden in advanced disease. Furthermore, chromatin modulation with trichostatin A or 5-aza-2'-deoxycytidine elevates USP9X expression in human PDA cell lines, indicating a clinical approach for certain patients. The conditional deletion of Usp9x cooperated with Kras(G12D) to accelerate pancreatic tumorigenesis in mice, validating their genetic interaction. We propose that USP9X is a major tumour suppressor gene with prognostic and therapeutic relevance in PDA.